Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: post hoc analyses of placebo-controlled trials in adults with severe constipation

Cash BD, et al. Neurogastroenterol Motil. 2023

Influence of demographic factors on clinical outcomes in adults with chronic idiopathic constipation treated with plecanatide

Rao SSC, et al. Clin Transl Gastroenterol. 2023

Best practices for the management of chronic idiopathic constipation and irritable bowel syndrome with constipation: a roundtable discussion and review 

Brenner DM. American Journal of Gastroenterology [Supplement]. 2022.

Real-world treatment strategies to improve outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation 

Brenner DM, et al. American Journal of Gastroenterology [Supplement]. 2022.

Burden of constipation: looking beyond bowel movements 

Harris LA, et al. American Journal of Gastroenterology [Supplement]. 2022.

Effective communication strategies and tools for improving treatment outcomes in patients with chronic idiopathic constipation and irritable bowel syndrome with constipation 

Kassebaum-Ladewski A, et al. American Journal of Gastroenterology [Supplement]. 2022

Mechanisms of action of current pharmacologic options for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation 

Sayuk GS, et al. American Journal of Gastroenterology [Supplement]. 2022.

The effect of acid suppression therapy on the safety and efficacy of plecanatide: analysis of randomized phase III trials 

Moshiree B, et al. Clinical Therapeutics. 2022.

Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders 

Sharma A, et al. Alimentary Pharmacology & Therapeutics. 2021.

Diagnosing constipation spectrum disorders in a primary care setting 

Heidelbaugh J, et al. Journal of Clinical Medicine. 2021.

Plecanatide is effective and safe in the treatment for chronic idiopathic constipation: results of a phase II trial

Barish C, et al. Digestive Diseases and Sciences. 2021.

Evaluation of plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in patients 65 years or older

Menees SB, et al. Clinical Therapeutics. 2020.

Blunted evoked prouroguanylin endocrine secretion in chronic constipation

Waldman SA, et al. Clinical and Translational Gastroenterology. 2019.

Comment on meta analysis by Shah et al

Griffin PH. American Journal of Gastroenterology. 2018.

Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders

Waldman SA, et al. Gut. 2018.

Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: focus on plecanatide

Martinez de Andino N. Journal of the American Association of Nurse Practitioners. 2018.

Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation 

Rao SSC. Therapeutic Advances in Gastroenterology. 2018.

Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study 

Barish CF, et al. Current Medical Research and Opinion. 2018.

The better understanding and recognition of the disconnects, experiences, and needs of patients with chronic idiopathic constipation (BURDEN-CIC) study: results of an online questionnaire

Harris LA, et al. Advances in Therapy. 2017.

Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation

DeMicco M, et al. Therapeutic Advances in Gastroenterology. 2017.

Response to Currie et al 

Miner PB. American Journal of Gastroenterology. 2017.

A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation 

Miner PB Jr, et al. American Journal of Gastroenterology. 2017.

Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog

Brancale A, et al. Pharmacology Research & Perspectives. 2017.

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses

Shailubhai K, et al. Digestive Diseases and Sciences. 2013.